BUZZ-Beam Therapeutics falls after patient death in early trial

Reuters11-05 23:39

** Shares of biotech firm Beam Therapeutics fall 3.30% to $23.56

** A patient with sickle cell disease has died due to respiratory failure in an early-to-mid stage trial of company's CRISPR-based cell therapy, BEAM-101, according to an abstract

** Respiratory failure was likely related to conditioning of a chemotherapy called busulfan, which is used to prepare patients for infusion

** The death occurred four months after infusion

** Company says eight patients have been dosed with BEAM-101

** "While the patient death is unfortunate, we see the event as highlighting the need for less-toxic preconditioning options" - William Blair

** Vertex and CRISPR Therapeutics' Casgevy and bluebird bio's Lyfgenia is approved for the treatment of sickle cell disease, which is a group of inherited blood disorders

** BEAM's Q3 net loss was $96.7 million, or $1.17 per share, compared with $96.1 million, or $1.22 per share, a year ago

** BEAM stock down ~15% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment